Skip to content

Depression: all studies

Page 82 of 1,034: studies 811 to 820 of 10,336, newest first. Back to the depression overview

Research

Exploring Esketamine's Therapeutic Role for Perinatal Depression via TASK-1 Tandem Pore Potassium Channels.

ACS Chemical Neuroscience July 29, 2025 Lin Zhu, Ji Chen, Yuan Liu et al. 1 citation

This research focuses on the promising use of esketamine in perinatal depression, a widespread disorder impacting postpartum women's mental health. Despite esketamine's known rapid antidepressant effects, its precise mechanisms are not fully understood. This study integrates clinical and preclinical approaches to explore esketamine's efficacy in treating perinatal depression and its actions...

Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group.

Psychiatry Research July 26, 2025 Giacomo D’andrea, Clara Cavallotto, Mauro Pettorruso et al. 16 citations

INTRODUCTION Anhedonia, defined as the diminished ability to experience or anticipate pleasure, is a core symptom of major depressive disorder (MDD) and bipolar depression (BD), and associated with depression severity, suicidality and poor treatment outcomes. Conventional antidepressants demonstrate limited efficacy against anhedonia. Esketamine nasal spray (ESK-NS) - a novel NMDA receptor...

Effectiveness of mindfulness-based cognitive therapy via e-health on anxiety and depression in adults: A meta-analysis.

General Hospital Psychiatry July 24, 2025 Shizhen Wang, Mengru Wu, Jixiang Wei et al. 6 citations

Anxiety and depression are highly prevalent mental health disorders, imposing significant burdens on individuals and healthcare systems. Mindfulness-based cognitive therapy (MBCT) has demonstrated effectiveness in reducing these symptoms. Electronic health MBCT (eMBCT) offers a scalable alternative, but its efficacy in alleviating anxiety and depression in adults remains unclear. To examine the...

Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.

Nature Medicine July 24, 2025 Luke A. Jelen, David J Lythgoe, James Stone et al. 29 citations

We investigated the potential role of the opioid system in modulating glutamatergic effects of ketamine administration in major depressive disorder. Twenty-six adults with major depressive disorder participated in a double-blind crossover study, receiving oral placebo or 50 mg naltrexone before an intravenous infusion of 0.5 mg per kg ketamine. Brain glutamatergic activity in the anterior...

DOI: 10.1038/s41591-025-03800-w (opens in new tab) Full text (opens in new tab) Ketamine Depression treatment Opioid system Mechanism of action

Effectiveness of Mindfulness-Based Stress Reduction on Salivary Cortisol and α-amylase Level, Anxiety and Depression in Students: A Randomized and Parallel-Group Clinical Trial.

Applied Psychophysiology and Biofeedback July 22, 2025 Saba Hassanvandi, Reza Mohammadzadegan, Seyed Hassan Saadat et al.

The current trial aimed to assess the effectiveness of Mindfulness-Based Stress Reduction training on salivary cortisol and α-amylase levels, anxiety and depression of students. This research was an experimental trial with a pre-test-post-test design and a control group. The statistical population of the research included all students studying in the universities of Khoy, Iran in 2021. The...

Perturbing whole‐brain models of brain hierarchy: An application for depression following pharmacological treatment

Annals of the New York Academy of Sciences July 21, 2025 Marcel Socoró-garrigosa, Yonatan Sanz Perl, Morten L. Kringelbach et al. 3 citations

Abstract Determining the scale of neural representations is a central challenge in neuroscience. While localized representations have traditionally dominated, evidence suggests information is also encoded in distributed, hierarchical networks. Recent research indicates that the hierarchy of causal influences shaping functional patterns serves as a signature of distinct brain states, with...

Nonresponse to Ketamine in Treatment‐Resistant Bipolar Depression

Neuropsychopharmacology Reports July 20, 2025 Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek et al. 3 citations

OBJECTIVES: Ketamine is a prototypical rapid-acting antidepressant for treatment-resistant bipolar depression (TRBD), yet many patients do not achieve a meaningful response. This study explored features of ketamine nonresponse in TRBD. METHODS: In a post hoc analysis of a naturalistic study, 35 TRBD patients received a four-week ketamine regimen (intravenous 0.5 mg/kg or oral 2.0/2.5 mg/kg)....

Insomnia and Esketamine Add-On Therapy to Antidepressant Therapy in Patients with Treatment-Resistant Depression-A Pilot Study.

Pharmaceuticals July 19, 2025 Daniel Szawarnoga, Joanna Fojcik, Michał Górski et al. 1 citation

Background: Insomnia, as one of the most common sleep disorders, is a significant health problem, especially among patients suffering from drug-resistant depression. Problems related to the quality of sleep in that population can significantly affect the effectiveness of treatment and quality of life, which is why it is necessary to search for effective therapeutic interventions in this area....

The sustained effect of 5-week EmotionCore mindfulness training on emotion regulation and emotional intelligence: heterogeneous benefits for depression and anxiety across subgroups

Frontiers in Psychiatry July 18, 2025 Hui Kou, Wei Luo, Yiwei Wang et al. 2 citations

Background: The present study investigated the sustained effects of a 5-week EmotionCore mindfulness training program on emotion regulation, emotional intelligence (EI), trait mindfulness, depression, and anxiety among 120 undergraduates, while exploring the mediating mechanisms of training effect and heterogeneous effects across subgroups. Methods: Participants were randomly assigned to a...

The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal

ACS Pharmacology & Translational Science July 16, 2025 Tobías Fernández-Borkel, Lucas F Borkel, Jaime Rojas-Hernández et al. 3 citations

The therapeutic potential of psychedelic substances, particularly psilocybin, for treatment-resistant depression (TRD) has garnered considerable attention. However, the necessity of subjective psychedelic experiences for therapeutic efficacy remains unclear, creating a critical gap in the field. To determine whether subjective psychedelic experiences induced by psilocybin are required for its...

DOI: 10.1021/acsptsci.5c00445 (opens in new tab) Consciousness Depression economics Psychotherapist Clinical psychology +2